Q-omics provides the consensus-scored GAPDHP46 profile across patient tissues and cancer cell-line models. GAPDHP46 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GAPDHP46 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, GAPDHP46 RNA expression shows 8,428 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UVM, KIRC, and HNSC as cancer lineages where GAPDHP46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP46 survival associations across molecular data types. GAPDHP46 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP46 RNA expression–survival associations across cancer types. High GAPDHP46 expression shows unfavorable associations in UVM, LIHC, SARC, BRCA and UCEC, but favorable associations in LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GAPDHP46 RNA expression.
This table summarizes GAPDHP46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP46 shows higher tumor expression in KIRC, BRCA, HNSC, THCA, COAD and LUSC. The KIRC box plot shows higher GAPDHP46 RNA expression in tumor versus normal tissue (log2 FC = +0.061, t-test p < 0.001).
This table shows molecular features associated with GAPDHP46 in patient tissues and cancer cell lines. In patient samples, GAPDHP46 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
